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The Value of 18F-Fluorodeoxyglucose Positron
Emission Tomography/Computed
Tomography for Staging of Primary
Extranodal Head and Neck Lymphomas
Thomas Schrepfer, MD; Stephan K. Haerle, MD; Klaus Strobel, MD; Niklaus Schaefer, MD;
Roger A. Ha¨lg; Gerhard F. Huber, MD
Objectives/Hypothesis: Using a retrospective
approach, the aim of this study was to confirm the
previously described value of fluorine-18-fluorodeoxy-
glucose positron emission tomography/computed to-
mography (18F-FDG-PET/CT) in patients with pri-
mary extranodal lymphoma of the head and neck
region. Additionally, the clinical significance of the
semiquantitative analysis of the standardized uptake
value (SUV), its predictive role in the follow-up set-
ting, and its value in detection of synchronous pri-
maries were studied.
Study Design: Retrospective chart review.
Methods: Twenty-six patients with a primary
extranodal head and neck lymphoma (22 diffuse large B-
cell lymphoma, one Hodgkin’s lymphoma, three malig-
nant T-cell lymphomas) were included. We retrospec-
tively evaluated the clinical outcomes according to the
maximum standardized uptake values of the primary
lesion (SUVmax) and whether a positron emission tomog-
raphy/computed tomography (PET/CT) was performed
or not in the follow-up studies. The median SUVmax was
chosen as the cutoff value. The patients were then
grouped as those with either low or high SUVmax, re-
spective to the cutoff value. Event-free survival and cu-
mulative survival were endpoints of interest.
Results: Nineteen patients (73%) were above
the age of 60 years; the median age was 70 years
(range, 28–87 years). Most primary sites were in the
Waldeyer’s ring (15 patients, 60%), whereas in four
patients (27%) only the palatine tonsil was affected.
The SUVmax ranged from 5.8 to 33.9. In one patient,
relevant fluorodeoxyglucose (FDG) uptake within the
intestine revealed a cecal adenocarcinoma as a sec-
ondary primary. Twenty of the 25 clinically followed
patients (80%) achieved complete remission after
treatment. Patients with high SUVmax showed favor-
able survival (log-rank test, P ¼ .044). A tendency for
longer survival within the group with follow-up PET/
CT studies could be noted but with no significant sta-
tistical difference (P ¼ .349).
Conclusions: 18F-FDG-PET/CT imaging is a
potent primary staging tool. It also has application as
an instrument for evaluation of follow-up and response
to therapy in patients suffering from primary extrano-
dal lymphoma and for detection of secondary malig-
nancies. Furthermore, 18F-FDG uptake by the primary
lesion may be related to better survival.
Key Words: Fluorine-18-fluorodeoxyglucose
positron emission tomography/computed tomography,
initial staging, lymphoma, head and neck.
Level of Evidence: 2b.
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INTRODUCTION
The incidence of non-Hodgkin’s lymphoma (NHL)
strongly depends on geographical and ethnic differences
and varies from 2/100,000 per year among the Asian
population to about 10/100,000 in Caucasians in North
America and Europe.1 It is the second most common
neoplasm in the head and neck region and should
always be considered in the differential diagnosis of a
unilateral neck mass.2 Extranodal lymphoma is present
in 25% to 40% of all NHL patients. Located within the
head and neck region, the Waldeyer’s ring (including
nasopharynx, tonsils, and base of tongue) is the major
site for malignant lymphoma. Within this anatomical
location, the tonsils are involved in 80%, and diffuse
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large B-cell lymphoma (DLBCL) is the most common his-
tological subtype.3–5 The peak incidence is in the sixth
and seventh decade with a male predominance.6
The standard treatment for patients with DLBCL
is nonsurgical. It consists of immunochemotherapy
using primarily cyclophosphamide, doxorubicin, vincris-
tine, and prednisone; concomitant radiotherapy, or
radiotherapy alone. The addition of rituximab, a mono-
clonal antibody, has significantly improved the overall
outcome.7–10
Fluorine-18-fluorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG-PET/CT)
imaging is increasingly used in many centers for staging
and assessment of the therapeutic response in patients
diagnosed with lymphoma. Several studies have shown
better performance of 18F-FDG-PET/CT for accurately
staging lymphomas compared to computed tomography
(CT) alone. Furthermore, for assessment of the response
to therapy, positron emission tomography/computed to-
mography (PET/CT) has high prognostic value with
respect to overall and event-free survival.11–14 The semi-
quantitative measurement of the standardized uptake
value (SUV), an easy-to-calculate and noninvasive index
of the 18F-FDG metabolic rate, has been assessed for its
additional prognostic value in early response and long-
term outcome in lymphoma patients. It improves the
prognostic value of early 18F-FDG PET/CT compared
with visual analysis in DLBCL.15,16
The outcomes of interest are the following: 1) con-
firm the previously described value of 18F-FDG- PET/CT
in patients with primary extranodal lymphoma of the
head and neck region and evaluate the clinical signifi-
cance of the semiquantitative analysis of SUV values,
and 2) determine the predictive role of 18F-FDG- PET/
CT in the follow-up setting.
MATERIALS AND METHODS
In a retrospective chart review, 26 patients who presented
with primary extranodal head and neck lymphoma between
January 2002 and December 2008 at the Department of Otorhi-
nolaryngology–Head and Neck Surgery, University Hospital
Zurich, Switzerland, were analyzed. Inclusion criteria were: all
patients with signs and symptoms only within the head and
neck area, cyto- and/or histopathologically proven malignant
lymphoma, 18F-FDG-PET/CT performed at initial staging, and
no other diagnosis of head and neck cancer at the time of
presentation.
Cyto- and histopathologic diagnosis was performed on the
basis of morphology and immunohistochemistry by our clinical
pathology department.
Especially in patients where both sites (nodal and extrano-
dal) are involved, the exact definition of primary extranodal
lymphoma is controversial.17 Diffuse large B-cell lymphoma and
Hodgkin’s lymphoma arising within the parotid gland were con-
sidered to be a primary extranodal.
PET/CT Data Acquisition
All imaging and data acquisition was performed on a com-
bined PET/CT in-line system (Discovery LS, STE or RX;
General Electric Medical Systems, Waukesha, WI). This device
integrates a PET scanner with a multislice helical CT and per-
mits the acquisition of coregistered CT and PET images in the
same session. First, an unenhanced CT scan (80 mA, 0.5 s/rota-
tion, 140 kV, reconstructed slice thickness 4.25 mm) from the
head to the pelvic floor was acquired for attenuation correction.
Consecutively, the table position was moved axially to the initial
position for the PET scan so that the first field of view covered
the pelvic floor and the bladder. Seven cradle positions were
scanned with a 2- to 4-minute emission scan per cradle position.
PET images were acquired during tidal breathing, and CT scans
were acquired during breath-hold. Before examination, patients
stayed nil per os for at least 4 hours before the intravenous
administration of an average of 10 mCi (370 MBq) of 18F-FDG.
Additionally, an oral contrast agent (Micropaque Scanner; Guer-
bet AG, Aulnay-sous-bois, France) was given. Imaging started
60 minutes after the 18F-FDG injection. The patient was posi-
tioned on the table in a head-first supine position. The arms of
the patients were placed in an elevated position above the abdo-
men to reduce beam hardening artifacts at the level of the liver.
The PET images were reconstructed using a standard iterative
algorithm (ordered subsets expectation maximization, two itera-
tive steps) and reformatted into axial, coronal, and sagittal views.
The acquired images were viewed with software providing
multiplanar reformatted images in all planes. Attenuation-cor-
rected PET images were used for analysis. Lesions were
interpreted as malignant if the uptake was higher than the
uptake of the surrounding background tissue. Increased 18F-FDG
uptake in well-known benign lesions or tissues such as brown fat
were excluded from analysis. The intensity of 18F-FDG uptake
was quantified by calculating the SUVmax for every pathologic
lesion. Furthermore, morphological findings of suspicious lesions
provided by the low-dose CT component were also used for inter-
pretation. The SUV was calculated using the formula: SUV ¼
(activity/unit volume)/(injected dose/total body weight). The SUV
of the primary extranodal site was denoted as the SUVmax.
Statistical Analysis
To estimate the patients’ outcomes in association with fol-
low-up PET/CT studies and its correlation to the SUVmax,
event-free survival (EFS) and cumulative survival (CS) were
chosen as endpoints. EFS was defined as the date of enrollment
to the time of progression, relapse, or death from any cause.
The impact of SUVmax on EFS as a continuous variable
was first evaluated using a Cox model. The reformulation of the
proportional hazards regression of Andersen and Gill in combi-
nation with the Efron approximation for tie handling was used
to explore survival differences. To predict EFS according to the
SUVmax value as a prognostic index, receiver operating charac-
teristic (ROC) analysis was performed. Because no significant
correlation could be shown in our series, no cutoff value could
be determined by the ROC curve. Therefore, we decided to take
the median SUVmax as a cutoff value. The patients were then
grouped as those with either low or high SUVmax.
The Kaplan-Meier estimates for EFS were calculated for
groups of patients with either high or low SUVmax and patients
with or without follow-up PET/CT. The survival functions of the
different groups were compared using the log-rank test. The
statistical analyses were performed using R18 version 2.8.1, and
significance level was set at the .05 level.
RESULTS
Patients’ Characteristics
The patients’ clinical characteristics are summar-
ized in Table I, and gender and age distribution are
shown in Figure 1. Median age was 70 years (range, 28–
87 years) with 73% of patients (19) aged above 60 years.
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Six (86%) out of the seven patients below the age of 60
years were men.
Types of Lymphomas
In the majority of patients, histology revealed a
DLBCL. One patient presented with a Hodgkin’s lym-
phoma within the parotid gland. Three patients were
found to have a malignant T-cell lymphoma.
Localization of Lymphomas
Of the 25 patients with non-Hodgkin’s lymphoma,
most presented within the Waldeyer’s ring (15 patients,
60%, respectively); in four patients (27%) only the pala-
tine tonsil was affected (stage I), and in one patient the
hard palate along with lymph node metastases was
involved (stage III). In two patients (8%), the thyroid
gland without locoregional lymph node involvement was
found to be the primary site (stage I and II, respec-
tively). Overall, 12 patients (46%) presented with
additional involved lymph nodes; the predominant loca-
tion was supradiaphragmal (n ¼ 9, stage II). One
patient showed organ involvement (spleen, liver, stom-
ach), whereas the bone marrow was disease free (stage
IV). In one patient (3.8%) whole body 18F-FDG-PET/CT
showed a relevant 18F-FDG-uptake within the intestine
as shown in Figure 2. Further investigations, colono-
scopy, and later hemicolectomy were performed and
revealed cecal adenocarcinoma as a second primary. In
all observed patients with malignant T-cell lymphoma,
the primary site was the nasal or oral cavity (hard pal-
ate). In one case, the lymphoma showed destructive
involvement of the facial skin, maxillary and ethmoid
sinus, pterygoid muscle, and multiple locoregional lymph
node metastases (no. 26, stage II).
Bone marrow aspiration was performed in 16
patients (62%), which was shown to be disease free. In a
further six cases, the patient either refused or there was
no need for any additional intervention. The results of
the remaining four patients were not available or
inconclusive.
Stage of Lymphomas
When 18F-FDG-PET/CT was used as a primary
staging tool, one patient was found to have stage IV dis-
ease with multiple organ involvement (no. 17). Three
patients were diagnosed as stage III (infradiaphragmal
lymph nodes), whereas nine patients were in stage II
(supradiaphragmal lymph nodes). Thirteen patients
were found to have limited local disease (stage I). In
cases where 18F-PET/CT was performed for further
TABLE I.
Characteristics of 26 Patients With PENHL.
Characteristics Value No. of Patients
Age, yr
Median 70
Range 28–87
60 19
<60 7
Gender
Women 7
Men 19
Ann Arbor stage
I–II 22
II–III 4
Primary sites
Waldeyer’s ring 19
Non-Waldeyer’s ring 7
SUVmax
Median 11.90
Range 5.80–33.90
PENHL ¼ primary extranodal non-Hodgkin’s lymphoma; SUV ¼
standardized uptake value.
Fig. 1. Gender and age distribution.
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staging after a surgical intervention, that is, diagnostic
tonsillectomy with palate excision biopsy (patients no. 1,
5, 8, 14, 15) and total parotidectomy (patient no. 25), no
persistence of local metabolic active malignant lymphoid
tissue was found. Due to these findings, two out of these
six patients achieved complete elimination of disease by
surgery alone, and no further treatment (chemotherapy,
radiotherapy) was undertaken.
Clinical Outcome
The patients’ details, along with the course of treat-
ment, are listed in Table II. Treatment response and
follow-up could not be evaluated in one patient because
of noncompliance. Of the remaining 25 patients, 20
(80%) achieved complete remission after treatment. One
patient (no. 20) is still undergoing induction therapy but
showed complete clinical remission, whereas one patient
(no. 25) developed locoregional relapse. Three patients
(patients nos. 7, 24, 26) suffered from progressive dis-
ease and died within the observed time period. One
patient (no. 12) died because of metastasizing intestinal
adenocarcinoma, but showed complete remission of the
DLBCL. Of the 25 patients with consistent follow-up
data, five had died by December 2008. Of the three
patients with T-cell lymphoma, only one achieved full re-
covery, whereas one died as a consequence of the
disease, and one death was attributed to cardiac failure
due to septic shock (no. 26).
Primary Outcomes
Clinical significance of the semiquantitative
analysis of SUV values. The Cox proportional hazards
regression showed no significant relation for SUVmax
and EFS (21 observations, P ¼ .069). The hazard ratio of
0.703 even presents a trend toward lower survival times
for a decreased SUVmax. Considering this result, the
ROC curve for survival was not included to group the
patients according to the SUVmax as a prognostic index.
Therefore, the median was used as the cutoff value to
separate the patients into two groups of either high or
low SUVmax (median 11.90, minimum 5.80, maximum
33.90). The Kaplan-Meier estimates, showing the CS for
the two SUVmax groups, are depicted in Figure 3. The
log-rank test, which was used to investigate differences
in the survival times between the groups of high and
low SUVmax patients, disclosed a significant difference
(21 observations, P ¼ .044). In contrast to previous
results,19 the patients within the low SUVmax group
were associated with reduced survival.
Predictive role in the follow-up setting. The
cumulative survival, in relation to whether follow up
PET/CT was performed or not, was evaluated using
Fig. 2. Positron emission tomogra-
phy/computed tomography (PET/
CT) findings in a selected study
subject, a 71-year-old patient
(patient no. 12) at initial staging per-
formed by 18F-fluorodeoxyglucose
positron emission tomography/com-
puted tomography. Increased fluoro-
deoxyglucose (FDG) uptake in the
Waldeyer’s ring (maximum standar-
dized uptake value ¼ 14, asterisk)
and multiple left-sided cervical
lymph nodes (arrowhead) caused by
lymphoma involvement are shown.
Biopsy of Waldeyer’s ring showed
diffuse large B-cell lymphoma. Focal
pathologic FDG-uptake in the ileo-
cecal area was investigated with
colonoscopy and revealed an ade-
nocarcinoma of the colon as a sec-
ondary malignancy (arrow). [Color
figure can be viewed in the online
issue, which is available at www.
interscience.wiley.com.]
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Kaplan-Meier estimates. The corresponding survival
functions are shown in Figure 4. The comparison of the
two survival curves shows a tendency for longer survival
within the group with follow-up PET/CT studies, but no
statistically significant difference in survival time could
be found as assessed by a log-rank test (25 observations,
P ¼ .349).
DISCUSSION
18F-FDG-PET/CT is valuable for initial staging and
assessment of the patient’s response to treatment of pri-
mary head and neck lymphomas. It offers advantages
over conventional imaging techniques by including the
metabolic activity and the extension of the malignant
disease because it can differentiate between malignant
and nonmalignant lymph nodes smaller than 1 cm.
In a previously performed meta-analysis of 20 stud-
ies between 1997 and 2004, the sensitivity of 18F-FDG-
PET/CT was found to be 91% and the false positive rate
was 10% using a patient-based analysis. These rates
appeared to be higher in patients with Hodgkin’s disease
compared with those suffering from a non-Hodgkin’s
lymphoma.20 18F-FDG-PET/CT has not been considered
to be reliable for the staging of low-grade NHL, because
low metabolic activity correlates with low 18F-FDG
uptake.21 The optimal management in patients suffering
from a malignant lymphoma is strongly related to the
histological subtype and correct assessment of the
expansion of the disease (staging); patients with stage I
or II disease (Ann Arbor/Cotswold) usually receive short
Fig. 3. Overall survival rates accord-
ing to the standardized uptake value
(SUV)max.
Fig. 4. Overall survival rates accord-
ing to positron emission tomogra-
phy/computed tomography (PET/
CT) studies as a follow-up modality.
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courses of chemotherapy, whereas patients with
advanced-stage disease are treated by more extensive
courses and radiotherapy. Due to its higher accuracy,
18F-FDG-PET/CT has been suggested as a routinely
obtained modality in pretreatment staging of lymphoma,
avoiding overly aggressive chemotherapy and extended
field radiation (overtreatment).21 For diagnosing both
nodal and extranodal disease, 18F-FDG-PET/CT was
more accurate than CT alone and resulted in a change of
staging in 8% with nodal disease and in 16% with extra-
nodal disease.22,23
In our series, five patients out of 15 who presented
with the Waldeyer’s ring as the primary affected site
underwent a diagnostic tonsillectomy. Four of these
patients had only limited disease of the tonsils. Further-
more, one patient was treated with tonsillectomy alone
and no adjuvant chemotherapeutic regimen was neces-
sary due to the negative findings in the 18F-FDG-PET/CT
imaging. This exemplifies the value of 18F-FDG-PET/CT
and its implications to the extent of treatment. Here, the
application of chemotherapeutics was reserved as a sec-
ond-line treatment.
In our patient cohort, the overall outcome for
patients with primary head and neck lymphomas was
found to be independent of gender and age.
Recent studies from Byun et al.19 showed a cor-
relation between the SUVmax measured prior to any
treatment and the clinical outcome of NHL patients. The
results imply that high SUVmax is related to unfavorable
survival. However, the usefulness of SUV in predicting
outcome seems to be controversial. Results vary from
one institution to another and are influenced by many
factors, including the imaging delay after 18F-FDG injec-
tion or differences in individual uptake.15,24,25
Compared to the results from Byun et al., we found
high SUVmax in correlation with better survival. This
difference could be due to institutional variables for the
SUV, ethnicity, gender, and age differences. In our se-
ries, the median age was 70 years, with 73% of the
patients above 60 years; 73% were men. In the study by
Byun et al., the median age of patients at was 50 years,
and an almost equal gender distribution was described.
Our series shows an excellent overall outcome in every
age group, especially for the DLBCL. Because high 18F-
FDG uptake of malignant tissue is associated with a
high proliferation rate, one can assume that metabolic
imaging is an indicator of tumor aggressiveness, individ-
ual tumor chemosensitivity, or tumor resistance to the
planned treatment.
In our institution, 18F-FDG-PET/CT is used for
patients with suspected advanced primaries and/or me-
tastases. Its ability to detect a considerable number of
synchronous primaries at the initial staging has been
shown by Strobel et al. in patients with head and neck
squamous cell carcinoma with 8.0% prevalence.26 In
their series, focal 18F-FDG accumulations in the colon
were found in 3% of all evaluated patients (8.9% malig-
nant). Our study confirms this rate because we found
one patient out of 26 (3.8%) to have invasive colon can-
cer incidentally detected by 18F-FDG-PET/CT and
confirmed with endoscopy.
CONCLUSION
18F-FDG-PET/CT imaging is a valuable tool for
staging and as a follow-up modality for assessing the
therapeutic response of patients suffering from primary
extranodal lymphoma and in detecting secondary malig-
nancies. Furthermore, our results indicate that the
initially measured SUV may be associated with the clini-
cal outcome in patients with primary extranodal
lymphoma, but further studies with larger groups are
recommended.
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